Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Guardant Health, Inc. - Common Stock (NQ:GH)

45.79 +3.69 (+8.76%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,040,191
Open 42.32
Bid (Size) 45.12 (8)
Ask (Size) 45.67 (2)
Prev. Close 42.10
Today's Range 42.29 - 46.75
52wk Range 20.14 - 52.92
Shares Outstanding 101,298,669
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why Guardant Health Stock Surged Nearly 9% Higher Today
Via The Motley Fool
Exposures Product Safety
Why Is Cancer Diagnostic Guardant Health Stock Trading Higher On Tuesday?
Guardant Health's Shield test receives FDA breakthrough status and NCCN guideline inclusion, with high accuracy shown in new ASCO and ECLIPSE study data. 
Via Benzinga
Exposures Product Safety

Performance

YTD
+44.1%
+44.1%
1 Month
-4.6%
-4.6%
3 Month
+7.9%
+7.9%
6 Month
+29.4%
+29.4%
1 Year
+75.0%
+75.0%

More News

Read More
Signet Posts Upbeat Earnings, Joins Ferguson Enterprises, Dollar General And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
FDA Grants Breakthrough Device Designation to Guardant Health’s Shield Multi-Cancer Detection (MCD) Test
From Guardant Health, Inc.
Via Business Wire
National Comprehensive Cancer Network (NCCN) Updates Colorectal Cancer Screening Guidelines to Include Shield Blood-Based Screening
From Guardant Health, Inc.
Via Business Wire
SERENA-6 Phase III Trial Demonstrates Clinical Value of Guardant360 CDx Test to Detect Emergence of Endocrine Resistance and Inform a Switch in Therapy Before Radiological Disease Progression in Advanced Breast Cancer
From Guardant Health, Inc.
Via Business Wire
In Largest Molecular Residual Disease (MRD) Study in Colon Cancer, Guardant Reveal Testing Prior to Chemotherapy Provides Robust Stratification for Risk of Disease Recurrence and Survival to Enable Timely Treatment Decisions
From Guardant Health, Inc.
Via Business Wire
2 Growth Stocks with Impressive Fundamentals and 1 to Question
Via StockStory
Exposures COVID-19
Firing on All Cylinders: Guardant Health (NASDAQ:GH) Q1 Earnings Lead the Way
Via StockStory
Guardant Health Introduces Nearly a Dozen Groundbreaking Smart Liquid Biopsy Applications for Guardant360 Liquid Test
From Guardant Health, Inc.
Via Business Wire
Guardant Health and Collaborators to Present Over 19 Studies Demonstrating Role of Liquid Biopsy in Advancing Precision Oncology at 2025 ASCO Annual Meeting
From Guardant Health, Inc.
Via Business Wire
Guardant Health, Evolent Health, Charles River Laboratories, Avantor, and Lumen Stocks Trade Down, What You Need To Know
Via StockStory
Topics Bonds Stocks
Exposures Debt Markets US Equities
Guardant Health Introduces Comprehensive Immunohistochemistry Testing for Solid Tumors
From Guardant Health, Inc.
Via Business Wire
Guardant Health Introduces Hereditary Cancer Testing to Identify Inherited Predispositions to Certain Types of Cancer
From Guardant Health, Inc.
Via Business Wire
Guardant Health: A Promising Player in the Liquid Biopsy Market
Via The Motley Fool
GH Q1 Earnings Call: Guardant Health Lifts Full-Year Guidance Following Oncology and Screening Momentum
Via StockStory
2 Volatile Stocks Worth Investigating and 1 to Steer Clear Of
Via StockStory
Topics Stocks
Exposures US Equities
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Guardant Health to Participate in Upcoming Investor Conferences
From Guardant Health, Inc.
Via Business Wire
TIME Names Guardant Health Co-CEOs to 2025 TIME100 Health List of the 100 Most Influential People in Global Health This Year
From Guardant Health, Inc.
Via Business Wire
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Guardant Health, Inc.
Via Business Wire
Netflix, CNA Financial And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
Cathie Wood Pours $9.8 Million In Robinhood Despite Crypto Revenue Slump, Keeps Dumping Palantir Ahead Of Earnings
Via Benzinga
Guardant Health’s (NASDAQ:GH) Q1: Strong Sales, Stock Soars
Via StockStory
Guardant Health Reports First Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
From Guardant Health, Inc.
Via Business Wire

Frequently Asked Questions

Is Guardant Health, Inc. - Common Stock publicly traded?
Yes, Guardant Health, Inc. - Common Stock is publicly traded.
What exchange does Guardant Health, Inc. - Common Stock trade on?
Guardant Health, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Guardant Health, Inc. - Common Stock?
The ticker symbol for Guardant Health, Inc. - Common Stock is GH on the Nasdaq Stock Market
What is the current price of Guardant Health, Inc. - Common Stock?
The current price of Guardant Health, Inc. - Common Stock is 45.79
When was Guardant Health, Inc. - Common Stock last traded?
The last trade of Guardant Health, Inc. - Common Stock was at 06/03/25 04:00 PM ET
What is the market capitalization of Guardant Health, Inc. - Common Stock?
The market capitalization of Guardant Health, Inc. - Common Stock is 4.64B
How many shares of Guardant Health, Inc. - Common Stock are outstanding?
Guardant Health, Inc. - Common Stock has 5B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.